scholarly journals A human papillomavirus vaccination program for low-income postpartum women

2016 ◽  
Vol 215 (3) ◽  
pp. 318.e1-318.e9 ◽  
Author(s):  
Abbey B. Berenson ◽  
Mahbubur Rahman ◽  
Jacqueline M. Hirth ◽  
Richard E. Rupp ◽  
Kwabena O. Sarpong
Keyword(s):  
Human Papillomavirus ◽  
Low Income ◽  
Vaccination Program ◽  
Postpartum Women ◽  
Human Papillomavirus Vaccination

scholarly journals School-based human papillomavirus vaccination program for increasing vaccine uptake in an underserved area in Texas

2019 ◽  
Vol 8 ◽  
pp. 100189 ◽  
Author(s):  
Sapna Kaul ◽  
Thuy Quynh N. Do ◽  
Enshuo Hsu ◽  
Kathleen M. Schmeler ◽  
Jane R. Montealegre ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Vaccine Uptake ◽  
Vaccination Program ◽  
Underserved Area ◽  
Human Papillomavirus Vaccination ◽  
School Based

scholarly journals Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries

2020 ◽  
Vol 5 (10) ◽  
pp. e003006
Author(s):  
Jessica Ochalek ◽  
Kaja Abbas ◽  
Karl Claxton ◽  
Mark Jit ◽  
James Lomas
Keyword(s):  
Human Papillomavirus ◽  
Low Income ◽  
Hpv Vaccination ◽  
Cost Effective ◽  
Health Impact ◽  
Healthcare Intervention ◽  
Human Papillomavirus Vaccination ◽  
Middle Income ◽  
Maximum Price ◽  
Healthcare Interventions

IntroductionEstimating the value of providing effective healthcare interventions in a country requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the resources required had, instead, been made available for other healthcare activities in that country. This potential alternative use of the same resources represents the health opportunity cost of providing the intervention. Without such assessments, there is a danger that blanket recommendations made by international organisations will lead to the adoption of healthcare interventions that are not cost effective in some countries, even given existing donor mechanisms intended to support their affordability.MethodsWe assessed the net health impact to 46 Gavi-eligible countries of achieving one of the WHO’s proposed 90-70-90 targets for cervical cancer elimination, which includes 90% coverage of human papillomavirus (HPV) vaccination among girls by 15 years of age, using published estimates of the expected additional benefits and costs in each country and estimates of the marginal productivity of each healthcare system. We calculated the maximum price each country could afford to pay for HPV vaccination to be cost effective by assessing the net health impact that would be expected to be generated at different potential prices.ResultsAt Gavi negotiated prices, HPV vaccination offers net health benefits across most Gavi-eligible countries included in this study. However, if Gavi-eligible countries faced the average price faced by non-Gavi eligible countries, providing HPV vaccination would result in reduced overall population health in most countries.ConclusionEstimates of the net health impact of providing a healthcare intervention can be used to assess the benefit (or lack of) to countries of adhering to global guidance, inform negotiations with donors, as well as pricing negotiations and the value of developing new healthcare interventions.

scholarly journals Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan

Sexual Health ◽  
2015 ◽  
Vol 12 (6) ◽  
pp. 520 ◽  
Author(s):  
Luke B. Connelly ◽  
Ha N. D. Le
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Screening Program ◽  
Vaccine Coverage ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
The Cost

Background Human papillomavirus (HPV) vaccines and their widespread adoption have the potential to relieve a large part of the burden of cervical cancer morbidity and mortality, particularly in countries that have low screening rates or, like Japan, lack a cohesive universal screening program. An economic evaluation was conducted to assess the cost-effectiveness of introducing a bivalent HPV vaccination program in Japan from a healthcare perspective. Methods: A Markov model of the natural history of HPV infection that incorporates both vaccination and screening was developed for Japan. The modelled intervention, a bivalent HPV vaccine with a 100% lifetime vaccine efficacy and 80% vaccine coverage, given to a cohort of 12-year-old Japanese girls in conjunction with the current screening program, was compared with screening alone in terms of costs and effectiveness. A discount rate of 5% was applied to both costs and utilities where relevant. Results: Vaccination alongside screening compared with screening alone is associated with an incremental cost-effectiveness ratio (ICER) of US$20 315 per quality-adjusted-life-year gained if 80% coverage is assumed. The ICER at 5% coverage with the vaccine plus screening, compared with screening alone, is US$1158. Conclusion: The cost-effectiveness results suggest that the addition of a HPV vaccination program to Japan’s cervical cancer screening program is highly likely to prove a cost-effective way to reduce the burden of cervical cancer, precancerous lesions and HPV16/18-related diseases.

scholarly journals PIN68 Cost- Effectiveness Analysis of Human Papillomavirus Vaccination Program in Russia

2011 ◽  
Vol 14 (7) ◽  
pp. A277-A278
Author(s):  
V. Omelyanovsky ◽  
M. Avxentyeva ◽  
I. Krysanov ◽  
O. Ivakhnenko ◽  
S. Goryaynov ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
Effectiveness Analysis
Sign in / Sign up

Export Citation Format

Share Document